Mindfulness-Based Stress Reduction to Improve Well-being in Black Adult Cancer Survivors, Community Faith-based Mindfulness Ministry
NCT ID: NCT06767475
Last Updated: 2025-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
115 participants
INTERVENTIONAL
2024-12-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota
NCT07291011
Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief
NCT05877521
Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer
NCT05763797
Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy
NCT02067351
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
NCT03538587
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Develop a culturally adapted Mindfulness-Based Stress Reduction (MBSR) intervention. (Phase 0) II. Pilot test the MBSR intervention to assess its feasibility, acceptability, and preliminary efficacy among a small group of participants. (Phase 0)
OUTLINE:
PHASE 0:
INTERVENTION DEVELOPMENT: Participants attend a focus group or a one-on-one interview over up to 60 minutes to gather insights of the cultural needs of Black adult cancer survivors.
PILOT TESTING: Patients participate in a group discussion with exercises and activities on study.
After completion of study intervention, patients are followed up at 3 months.
PHASE 1: Patients participate in group discussions, exercises, and activities over no more than 8 hours for up to 3 sessions (up to 16 hours total) within 8 weeks.
PHASE 2: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients participate in group discussions, exercises, and activities over no more than 8 hours for up to 3 sessions (up to 16 hours total).
GROUP II (CONTROL): Patients receive usual care on study.
After completion of study intervention, patients are followed up at 3 and 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (MBSR)
Patients participate in group discussions, exercises, and activities over no more than 8 hours for up to 3 sessions (up to 16 hours total).
Health Promotion
Participate in group discussion with exercises and activities
Questionnaire Administration
Ancillary studies
Group II (control)
Patients receive usual care on study.
Best Practice
Receive usual care
Questionnaire Administration
Ancillary studies
Phase 0 (intervention development, pilot testing)
INTERVENTION DEVELOPMENT: Participants may attend a focus group or a one-on-one interview over up to 60 minutes to gather insights of the cultural needs of Black adult cancer survivors.
PILOT TESTING: Patients participate in a group discussion with exercises and activities on study.
Discussion
Attend a focus group
Health Promotion
Participate in group discussion with exercises and activities
Interview
Attend a one-on-one interview
Questionnaire Administration
Ancillary studies
Phase 1 (MBSR)
Patients participate in group discussions, exercises, and activities over no more than 8 hours for up to 3 sessions (up to 16 hours total) within 8 weeks.
Health Promotion
Participate in group discussion with exercises and activities
Questionnaire Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Best Practice
Receive usual care
Discussion
Attend a focus group
Health Promotion
Participate in group discussion with exercises and activities
Interview
Attend a one-on-one interview
Questionnaire Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PHASE 0 DEVELOPMENT: Ability to speak, read and understand English
* PHASE 0 DEVELOPMENT: Individuals personally affected by cancer, either through their own diagnosis or that of a loved one
* PHASE 0 DEVELOPMENT: Self-identifies as Black or African American
* PHASE 0 DEVELOPMENT: Membership or affiliation with a faith-based organization
* PHASE 0 PILOT TESTING: Adults aged 18 or older
* PHASE 0 PILOT TESTING: History of a cancer diagnosis
* PHASE 0 PILOT TESTING: Meets National Cancer Institute (NCI) cancer survivor definition (a person is a survivor from the time of diagnosis until the end of life)
* PHASE 0 PILOT TESTING: Ability to physically attend live MBI and complete web-based surveys and assessments
* PHASE 0 PILOT TESTING: Ability to speak, read and understand English
* PHASE 1: Adults aged 18 or older
* PHASE 1: History of a cancer diagnosis
* PHASE 1: Meets NCI cancer survivor definition (a person is a survivor from the time of diagnosis until the end of life)
* PHASE 1: Ability to physically attend live MBI and complete web-based surveys and assessments
* PHASE 1: Ability to speak, read and understand English
* PHASE 2: Adults aged 18 or older
* PHASE 2: History of a cancer diagnosis
* PHASE 2: Meets NCI Cancer Survivor definition (a person is a survivor from the time of diagnosis until the end of life)
* PHASE 2: Ability to physically attend live MBI and complete web-based surveys and assessments
* PHASE 2: Ability to speak, read and understand English
* PHASE 0 DEVELOPMENT: Unable or unwilling to participate in the recorded sessions
* PHASE 0 PILOT TESTING: Inability to attend and participate in MBI due to medical or psychological hardship
* PHASE 0 PILOT TESTING: Inability to speak, read and understand English
* PHASE 1: Inability to attend and participate in MBI due to medical or psychological hardship
* PHASE 1: Inability to speak, read and understand English
* PHASE 1: Participated in phase 0 of the study
* PHASE 2: Inability to attend and participate in MBI due to medical or psychological hardship
* PHASE 2: Inability to speak, read and understand English
* PHASE 2: Participated in phase 0 or phase 1 of the study
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Floyd B. Willis, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Floyd B. Willis, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Florida
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-10490
Identifier Type: REGISTRY
Identifier Source: secondary_id
MC240901
Identifier Type: OTHER
Identifier Source: secondary_id
24-006322
Identifier Type: OTHER
Identifier Source: secondary_id
MC240901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.